Zain Kassam's family didn't have a roadmap. His mother came to Canada as a refugee from East Africa, and his father's family had run a bakery in Kenya. As the son of immigrants, Zain grew up understanding there were really only three acceptable careers: doctor, lawyer, or engineer. He had little real exposure to any of them, and worked the counter at the family convenience store. Money was tight, but his parents understood that education was what would change his trajectory, and they sacrificed almost everything to put Zain and his brother through Montessori school and give him a better start. Alongside a fierce competitive streak and a handful of early talents, he developed an organic fascination with health and science, even racing middle school classmates to recite the taxonomic ranks. That early fascination with biology, health, and the unsolved edges of medicine would run through his entire career. Over time it sharpened into a focus on the gut, shaped in part by watching his father live with ulcerative colitis. His research began with a high-school stint at the Ottawa Health Research Institute, surviving a near-detour into competitive debating, where he ranked among the best in North America, before a meeting with a judge on the Supreme Court of Canada nudged him toward science rather than law. From there, Zain studied health sciences at McMaster, the birthplace of evidence-based medicine; trained in medicine at Western University in London, Ontario; returned to McMaster for Internal Medicine and Gastroenterology; earned an MPH in quantitative methods at Harvard's T.H. Chan School of Public Health; and pursued a postdoctoral fellowship in microbiome engineering at MIT.The combination is the point. Clinical GI, biostatistics, and engineering together helped Zain build a field rather than just practice in it. He was a co-founder and Chief Medical Officer of OpenBiome, the first public stool bank in the United States; co-founder and CMO of Finch Therapeutics, which he took through Phase II trials and a 2021 NASDAQ IPO; and is today CMO at Seed Health, an ARTIS portfolio company bringing evidence-based microbiome science directly to consumers. Behind the titles sit more than 200 peer-reviewed publications, 15 issued patents and patent applications, and a category of medicine that did not exist when he started.